Nicolas Mouawad
Vascular Surgery · West Branch, MINPI 1730388497
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Inari Medical, Inc. at 29.9% of the total. 2025 is the largest year on record at $363,920, 3.0 times the $122,047 reported in 2019. Among vascular surgery clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,272 payments — averaging $731.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$497K
- Endologix LLC$252K
- Shockwave Medical, Inc$196K
- Johnson & Johnson$117K
- Mimedx Group, Inc.$83K
- Medtronic$82K
- plus $435K from 54 others
Across 471 payments — averaging $1882.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$259K
- Inari Medical, Inc.$130K
- Penumbra, Inc.$103K
- Bard Peripheral Vascular, Inc.$102K
- Silk Road Medical, Inc.$83K
- Medtronic$53K
- plus $156K from 9 others
Across 5 payments — averaging $2617.38 each. An ownership or investment interest held by the physician or an immediate family member.
- Centerline Biomedical Inc.$13K
What the payments were for
- Consulting fees$641,40839%
- Speaking & faculty fees$702,26842%
- Travel & lodging$203,71012%
- Food & beverage$92,7136%
- Education$21,3401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$530,611
- FLOWTRIEVER CATHETER, S$498,136
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$186,983
- Alto Abdominal Stent Graft System$148,818
- XARELTO$114,711
- AFX$45,521
- Ovation$43,251
- ENROUTE Transcarotid Neuroprotection System$43,206
- EKOSONIC$42,626
- FlowTriever$35,653
- ClotTriever$35,653
- AFX2 Bifurcated Endograft System$30,367
- HawkOne$28,988
- GENERAL - THERAPIES$28,175
- TREO ABDOMINAL STENT-GRAFT SYSTEM$27,873
- ENROUTE Transcarotid Stent System$24,084
- ENHANCE Transcarotid Peripheral Access Kit$24,084
- ENROUTE 0.014 Guidewire$24,084
- BOVINE COLLAGEN$22,857
- GORE VIABAHN VBX Balloon Expandable Endo$20,490
How this compares
$1,661,439 in reported general payments places this provider in the 95th percentile of 183 vascular surgery providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 16 | $25,539 |
| ClopidogrelClopidogrel Bisulfate | 131 | $2,301 |
| Cilostazol | 34 | $1,165 |
| Atorvastatin Calcium | 21 | $228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $116,746 | $25,53916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 vascular surgery providers in Michigan.
Other vascular surgery in West Branch
- Enrique Criado PallaresMidland$800K
- Jordan KnepperEast Lansing$336K
- Joseph CuppariClinton Township$98K
- Eanas YassaGrand Rapids$81K
- Abedelkarim AbushmaiesBattle Creek$75K
- Kevin OnofreyDetroit$65K
- Yevgeniy RitsDetroit$57K
- Ryan KimSaginaw$50K
- Jimmy HaouilouSaint Clair Shores$45K
- Jonathan MurdockSaginaw$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.